Marker Therapeutics wins $16.2 million CPRIT grant for MT-601 Phase 2 study
MRKR•Marker Therapeutics secured a $16.2 million grant from the Cancer Prevention and Research Institute of Texas to support the planned Phase 2 APOLLO study of MT-601 in large B-cell lymphoma patients whose disease relapsed after CAR-T therapy.
1. Grant supports planned study
Marker Therapeutics secured $16.2 million in non-dilutive funding from the Cancer Prevention and Research Institute of Texas. The grant will support the planned Phase 2 APOLLO study of MT-601 in patients with large B-cell lymphoma whose disease relapsed following CAR-T therapy.




